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Abstract Therapy-related adverse side effects are a main
reason for non-persistence to adjuvant endocrine breast
cancer therapy. This study reports frequency of drug-related
adverse side effects that were so severe that a modification of
the therapy was necessary. We evaluated how many patients
discontinued adjuvant endocrine therapy because of these
side effects (non-persistence). Last, we analyzed how often a
drug switch was undertaken for this reason and how often
this measure led to the patient successfully continuing their
endocrine therapy. Data concerning all postmenopausal
breast cancer patients (B80 years), who initiated endocrine
adjuvant therapy between 1998 and 2008 in a Swiss breast
center (n = 400), were analyzed. Out of these 400 women,
37 (9.3%) were defined as being non-persistent to the ther-
apy; out of these, 24 (64.9%) because of therapy-related side
effects. About 78 patients (19.5%) suffered from severe
therapy-related side effects that made a modification of
therapy necessary. Out of these 78 cases, 14 patients (17.9%)
stopped the therapy without attempting a drug switch (non-
persistence). In 64 patients (82.1%; 16% of all women who
started endocrine therapy), a drug switch was undertaken.
Out of these 64 cases, in 52 cases (81.3%) endocrine therapy
was completed after therapy modification. Patients who
reported one major adverse effect were more likely to con-
tinue the endocrine therapy after a drug switch (P = 0.048)
compared with those who suffered from at least two different
side effects. In 10 of the 64 cases (15.6%), modification of the
therapy was not successful and the patients stopped the
treatment prematurely (non-persistence) because of ongoing
side effects. In cases when therapy-related side effects occur,
a drug switch is a promising step to further improve persis-
tence and, by doing so, the outcome of breast cancer patients.
Keywords Breast cancer  Endocrine therapy  Adverse
events  Switch  Persistence  Adherence
Introduction
Since the late 1990s, international guidelines recommend a
full 5 years of adjuvant systemic endocrine treatment with
tamoxifen for the vast majority of postmenopausal patients
with hormonal receptor (HR) positive breast carcinomas
[1]. More recently, clinical studies demonstrated additional
benefit with the third-generation aromatase inhibitors (AIs)
in postmenopausal women, either as initial management
also for 5 years, as sequential therapy following 2–3 years
use of tamoxifen, or as extended therapy following 5 years
of tamoxifen.
In long-term therapies, however, there are a multitude of
factors and clinical situations that threaten and prevent
completion of the targeted 5-year treatment. The main
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causes noted by patients for non-persistence/non-adherence
to therapy are drug-related adverse side effects such as
arthralgia, hot flashes and gynecologic symptoms [2–7].
Clinicians who are experienced in the follow-up of breast
cancer patients are aware of these issues and can offer a
multitude of nonpharmacological and pharmacological
treatment strategies, which alleviate the symptoms of side
effects [2–7]. In some cases, a drug switch is a promising
step [2]. However, to the best of our knowledge, there is
only one study which evaluated frequency and outcome of
side effect-related drug switches [8].
This study reports how often postmenopausal women
(diagnosed in a ten-year period from 1998 to 2008 in a
Swiss breast center) suffered from drug-related adverse
side effects in such a severity that a modification of the
therapy was necessary. Furthermore, we evaluated how
many patients discontinued their adjuvant endocrine ther-
apy due to these side effects (non-persistence). Lastly, we
analyzed how often a drug switch was undertaken for this
reason and how often this measure led to the patient suc-
cessfully continuing their endocrine therapy.
Patients and methods
Data concerning all postmenopausal non-metastatic breast
cancer patients up to and including the age of 80 years,
who received surgical therapy between 1998 and 2008 at
the Department of Gynecology and Obstetrics of the Uni-
versity Hospital Basel (Basel, Switzerland) and was col-
lected in the institutional prospective relational Basel
Breast Cancer Database (BBCD) form the basis of the
current analysis. Of these 523 patients, 427 had hormonal
receptor (HR) positive carcinomas (81.6%) and 96 had HR
negative tumors (18.4%). The 427 patients with HR posi-
tive carcinomas were evaluated in this study. We had
complete follow-up in 421 of these patients and six patients
were lost to follow-up after a median observation time of
16.5 months (range: 1–45 months).
The following clinicopathological and treatment data,
which is summarized in Table 1, was available for all
patients: age at initial diagnosis, tumor stage according to
the American Joint Committee on Cancer (AJCC)/Inter-
national Union Against Cancer (UICC) TNM Classification
[9, 10], histological subtype, grading, estrogen receptor
(ER) and progesterone receptor (PR) status, surgery type,
and receipt of adjuvant chemotherapy and/or radiation.
HER-2/neu status has been routinely assessed for all
patients since 2002; in our study group this variable was
available for 394 patients (92.3%).
The treatment recommendations for all patients were
based on the decision of the interdisciplinary tumor board
of the University Hospital Basel. As of 1997, adjuvant
endocrine therapy has been the standard recommendation
for all HR positive patients, with few exceptions. All
patients received a comprehensive consultation at the
Table 1 Clinicopathologic and treatment characteristics of 427 post-
menopausal women with hormonal receptor positive breast cancer
Variable Number (%)
Age (years)
Mean 65.9
Range 46–80
B60 years 128 (30.0)
61–75 165 (38.6)
[75 years 134 (31.4)
Hormonal receptor status
ER? PR? 311 (72.8)
ER? PR– 114 (26.7)
ER- PR? 2 (0.5)
Grading
G1 92 (21.6)
G2 235 (55.0)
G3 93 (21.8)
Not applicable 7 (1.6)
HER-2 neu status
Known 394 (92.3)
Positive 49 (12.4)
Histologic subtype
Ductal invasive 301 (70.5)
Lobular invasive 85 (19.9)
Rare types 41 (9.6)
AJCC/UICC stagea
I 209 (49.0)
II 166 (38.9)
III 52 (12.1)
Type of surgery
Mastectomy ? ALND 111 (26.0)
Mastectomy ? SLND 26 (6.1)
BCT ? ALND 149 (34.9)
BCT ? SLND 124 (29.0)
Mastectomy only 11 (2.6)
Tumorectomy only 6 (1.4)
Systemic treatment other than adjuvant endocrine therapy
Previous adjuvant chemotherapy 70 (16.4)
Neoadjuvant chemotherapy 4 (0.9)
Neoadjuvant endocrine therapy 2 (0.5)
Adjuvant treatment with trastuzumab 12 (2.8)
Adjuvant radiotherapy 308 (72.1)
ER estrogen receptor, PR progesterone receptor, AJCC American
Joint Committee on Cancer, UICC International Union Against
Cancer [9, 10], ALND axillary lymph node dissection, SLND sentinel
lymph node dissection, BCT breast-conserving therapy
a In six patients, where neoadjuvant therapy was performed, the ypT
and ypN status were used for stage grouping
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departmental oncology unit, during which treatment indi-
cation and duration, as well as the potential adverse effects,
were extensively discussed.
In order to systematically evaluate the different clinical
situations during the course of adjuvant endocrine therapy,
we created the following subdivisions (Table 2):
A. Patients who did not initiate therapy (n = 27).
This subgroup includes the patients to whom endocrine
therapy was not recommended (n = 8), and the patients
who refused the recommended therapy and never began
treatment (n = 19).
B. Patients who initiated therapy (n = 400).
Of the 400 patients who initiated endocrine therapy, 149
(37.3%) fully completed the targeted therapy after a five-
year course (three patients interrupted therapy for up to three
months, one patient for five months) and 44 (11.0%) had an
extended therapy [ 5 years (20 of these with an ongoing
therapy at the time of last follow-up in January–March
2011). As it was the intention of our study to evaluate
patients who discontinued therapy due to drug-related side
effects, which in most cases occurs within the first two years
of therapy [11–13], we also included patients with an
ongoing therapy who took their medication for at least
30 months (n = 106; 26.5%). Further subgroups must also
be considered as having completed therapy, although
treatment was not administered for the targeted five years:
13 patients discontinued the therapy due to death from
causes other than breast cancer (but medication was taken
until shortly before death); 40 patients ceased therapy due to
breast cancer recurrence and in five cases, the therapy was
discontinued by the physician due to serious medical rea-
sons independent from breast cancer disease and therapy-
related adverse effects (advanced age/dementia/need for
nursing home care, n = 2; incurable malignancy other than
breast cancer, n = 2; irreversible coma following severe
head trauma, n = 1).
Table 2 Course of endocrine
therapy
BC breast cancer
a Two patients who were lost to
follow-up but had an
observation time of more than
30 months were allocated to a
location of follow-up
Number
(%)
Mean age
(range)
Median duration
of therapy
(months)
Entire study group 427
No endocrine therapy recommended 8 (1.9) 68.5 (52–77)
Patients where endocrine therapy was recommended 419 (100)
Patients refused to initiate therapy 19 (4.5) 66.7 (52–79)
Patients who initiated endocrine therapy 400 (100)
Initial agent prescribed
Tamoxifen 265 (66.3)
Anastrozole 73 (18.3)
Letrozole 42 (10.5)
Exemestane 3 (0.7)
Fulvestrant 1 (0.2)
Blinded study medication (BIG 1–98 trial) 16 (4.0)
Therapy fully completed 299 (74.8) 65.4 (47–80)
Therapy discontinued because of death
(i.e., completed)
13 (3.3) 68.5 (52–79) 14 (2–48)
Therapy discontinued because of BC
recurrence (i.e., completed)
40 (10.0) 66.6 (47–80) 21.5 (3–58)
Therapy discontinued because of medical
reasons independent from BC and adverse effects from
the endocrine therapy (i.e., completed)
5 (1.3) 69.6 (60–75) 28 (25–52)
Non-persistence 37 (9.3) 67.1 (49–80) 15.5 (1–50)
Lost to follow-up 6 (1.5)
Location of follow-up 400 (100)
Own oncologic unit 268 (67.0)
External oncologic unit 40 (10.0)
General practitioner 88 (22.0)
Unknowna 4 (1.0)
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We distinguished the above-mentioned subgroups from
non-persistent patients patients who discontinued the
planned mode of treatment and refused to continue further
endocrine therapy (n = 37). In this context, non-persis-
tence was an intentional action of the patients in most
cases.
In this study, we used the term ‘‘persistence’’ and not
‘‘adherence’’. Persistence is defined as the length of time
from initiation to discontinuation of treatment; it is a
specific aspect of adherence, which is defined as the extent
to which patients take medications as prescribed [14–16].
Some other studies defined these terms differently and used
compliance, adherence and persistence sometimes inter-
changeably [4].
The initial endocrine agents prescribed are listed in
Table 2. Twenty-nine patients were treated within the
randomized, phase III, double-blind Breast International
Group (BIG) 1–98 four-arm study (letrozole or tamoxifen
as monotherapy or sequential therapy) [17]; the medication
was unblinded in 13 of these patients. In 48 patients, there
was an intended sequential therapy (switching after
2–3 years of adjuvant tamoxifen therapy to an aromatase
inhibitor) outside of a study protocol.
Finally, we recorded the location of treatment and fol-
low-up of the patients (our own oncology unit, external
oncology unit, or general practitioner).
Information concerning type and duration of the medi-
cation, as well as the reasons for discontinuation, was
obtained from the medical record. Patients who had no
follow-up at our institution were monitored via telephone.
Afterward, contact was made with the treating physician to
confirm the patients’ statements.
Data collection methods and the study design were
approved by the institutional review board.
Statistical analysis
Comparisons between nominal parameters were made with
the Fisher exact test. Comparisons between metric
parameters (age) were made with the Wilcoxon rank sum
test. To identify factors associated with A) the choice to
switch due to therapy-related side effects, and B) a switch
that led to a successful continuation of therapy, we created
two univariate logistic regression models. Each model
included the independent variables year of the initial
diagnosis, patient‘s age, axillary lymph node status, receipt
of previous chemotherapy, the antihormonal agent pre-
scribed, the number of the reported adverse effects, and
location of follow-up. Odds ratios (OR) with corresponding
95% confidence intervals (CI) were reported; a P-value\ 0.05
was considered significant. Statistical analyses were per-
formed with R Development Core Team software, version
2.5.0 (Vienna, Austria).
Results
Frequency of non-persistence
Out of the 400 women who started endocrine therapy, 37
(9.3%) were non-persistent to the initiated therapy; out of
these, 24 (64.9%) due to therapy-related side effects, and
13 (35.1%) due to other reasons. The main reasons for this
given by the patients are listed in Table 3.
Frequency of therapy modification due
to therapy-related side effects
Out of the 400 women who started endocrine therapy, in 78
patients (19.5%), the therapy-related side effects were so
severe, that a modification of the therapy (drug switch or
cessation) was indicated. Comparing the patients who
suffered from adverse therapy-related side effects that
made a modification of the therapy necessary to the ones
where this was not the case, there were no relevant dif-
ferences with regard to age (mean: 64.8 years vs.
66.0 years; P = 0.280) or initial agent taken (tamoxifen:
70.5% vs. 68.5%; P = 0.788).
Out of the above-mentioned 78 cases, 14 patients
(17.9%) stopped the therapy without attempting a drug
switch (non-persistence). In 64 patients (82.1%; 16% of all
women who started endocrine therapy), a drug switch was
undertaken. In our univariate calculation model (Table 4),
the number of major adverse effects was the only signifi-
cant predictive factor for drug switch (P = 0.044).
Effect of drug switch on persistence
Table 5 lists the sequence of drugs in the switch approaches.
Out of the 64 cases where a drug switch was made, in 52 cases
(81.3%) endocrine therapy was completed after therapy
modification; out of these, in 37 cases (71.2%) one drug
switch was made, in 12 cases (23.1%) two medication
changes were necessary and in three cases (5.7%) the med-
ication was changed three times. Table 3 lists the main
symptoms diagnosed or reported by the patients who com-
pleted therapy after drug switch. Patients who reported one
major adverse effect were more likely to continue the
endocrine therapy after a drug switch (P = 0.048, see
Table 4) compared to those who suffered from at least two
different side effects.
In 12 of the 64 cases (18.8%), modification of the
therapy was not successful and the patients stopped the
treatment prematurely (non-persistence). Ten patients
stopped the therapy due to ongoing or further side effects;
two women initially continued the therapy but stopped later
before the planned five years because they felt that therapy
was no more necessary in their situation (both patients
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were older and multimorbid women who wanted to reduce
the number of their drugs prescribed).
Discussion
Adjuvant endocrine treatment for breast cancer has a special
status within oncological therapies as its recommended
duration is not a few weeks or months, as in chemotherapy,
but at least five years. In the case adverse therapy-related
events occur, these mean more than only a transient
inconvenience for the patients [2]. Since endocrine therapy
is a systemic treatment which can affect almost every organ
system, there is a broad range of possible therapy-related
side effects. Venous thromboembolic events, hot flashes,
arthralgia and bone pain, as well as neuropsychiatric, gas-
trointestinal and gynecologic symptoms are frequently
reported adverse effects associated with endocrine therapy.
Careful recognition and competent management of these
side effects cannot be emphasized enough as adverse events
constitute the main reason for non-persistence and non-
adherence to endocrine treatment. This field is increasingly
becoming a focus of interest [2–7]. Aside from nonphar-
macological and pharmacological measures to alleviate or
Table 3 Main reasons for
modification of the
antihormonal therapya
a More than one symptom per
patient is possible
Non-persistence:
preterm stop of
the therapy (with or
without drug switch)
n = 24
Persistence: continuation/
completion of therapy after
drug switch n = 54
1. Patients who suffered from therapy-related side effects and modified the therapy, n = 78
General discomfort 6 7
Lack of energy 2 5
Sleeping difficulties 3 2
Night sweats 1 –
Nervous feelings 5 4
Mood swings 3 5
Head aches – 2
Dizziness 1 3
Nausea 4 4
Paresthesia at extremities 1 3
Visual disorders 2 2
Dermatologic disorders, hair loss 2 2
Gastrointestinal symptoms 1 1
Weight gain 1 2
Hot flashes 7 6
Venous disorders 1 2
Venous thromboembolic events 1 5
Ischemic cerebrovascular events 1 1
Hypertension 2 1
Virilization – 2
Endometrial hyperplasia – 2
Musculoskeletal events
(e.g., arthralgia, bone pain)
4 25
2. Patients stopped the therapy for reasons other than therapy-related side effects (n = 13)
Wish for discontinuation, lack of motivation 5
Lack of faith in the therapy 2
Misinformation by physician 1
Error regarding length of therapy 1
Insurance reasons 1
Denial of the cancer diagnosis 1
Alcohol dependency or psychiatric disease 2
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resolve these side effects, a switch to a different agent is a
valid option. However, to the best of our knowledge, there is
only one study which evaluated frequency and outcome of
side effect-related drug switches [8].
In our study cohort, approximately two third of the
patients, who were non-persistent to endocrine therapy,
stopped their treatment due to therapy-related side effects.
The non-persistence rate in our study, which lies at 9.3%, is
clearly in the lowest range of the reported data in adjuvant
endocrine breast cancer treatment both in clinical trials
[17–20] and in clinical practice settings [11–13, 15, 21–30].
To interpret these results accordingly, one must identify
how we defined non-persistence, which is the actual target
variable in our study. According to a previous study, we
clearly distinguished the terms ‘‘discontinuation of ther-
apy’’ and ‘‘non-persistence’’ and are of the opinion that non-
persistence to a long-term oral therapy is, in general, not
simply the act of stopping medication, but rather an inten-
tional action [11]. According to this principle, patients who
had to stop therapy due to local or systemic breast cancer
recurrence were not defined as being non-persistent. The
same holds true for cases where a physician decided to stop
the therapy for medical reasons other than breast cancer
(e.g. in palliative situation of malignant diseases, depen-
dence on nursing care, severe dementia); this subgroup was
introduced in one of our previous publications in the liter-
ature regarding therapy persistence/adherence in breast
cancer [11]. Furthermore, in accordance with most authors,
patients who died within the planned five years of treatment
from intercurrent illness and took the medication shortly
before death were not considered as non-persistent. We
place a great deal of importance on the above-mentioned
criteria because non-persistence as an intentional action
may be preventable by more intensive care and improved
counseling and a certain proportion of these patients may
potentially be motivated to maintain therapy; this
Table 4 Univariate relationships between potential predictors and
(A) a drug switch when adverse therapy-related side effects occurred
and (B) a successful continuation of endocrine therapy after a drug
switch
Variable Odds ratio 95% CI P value
(A)
Year of the initial diagnosis:
1998–2002 Reference
2003–2008 2.25 0.68–7.47 0.190
Advanced age 0.85a 0.56–1.30 0.455
Positive axillary lymph node
status
0.64 0.17–2.36 0.500
Previous chemotherapy 3.00 0.36–25.21 0.312
Initial antihormonal agent
Tamoxifen Reference
AI 0.48 0.15–1.59 0.232
Number of reported adverse effects
1 Reference
C2 0.27 0.08–0.97 0.044
Location of follow-up
Oncologic unit Reference
General practitioner 0.41 0.11–1.59 0.212
(B)
Year of the initial diagnosis
1998–2002 Reference
2003–2008 1.00 0.23–4.39 1.00
Advanced age 1.15a 0.71–1.85 0.573
Positive axillary lymph node
status
1.40 0.32–6.13 0.655
Previous chemotherapy n.a. n.a. 0.018
Initial antihormonal agent
Tamoxifen Reference
AI 2.38 0.64–8.88 0.197
Number of reported adverse effects
1 Reference
C2 0.26 0.07–1.00 0.048
Location of follow-up
Oncologic unit Reference
General practitioner 1.28 0.23–7.14 0.777
AI aromatase inhibitor, n.a. not applicable
a Odds ratio is expressed as the ratio of an increase within 5 years
Table 5 Sequence of agents in therapy switches
All
switches
Successful
switchesa
Failed
switchesb
Total number of therapy
switches
82 54 (65.9) 28 (34.1)
Tamoxifen ? Aromatase
inhibitor
36 21 (58.3) 15 (41.7)
Tamoxifen ? letrozole 25 13 12
Tamoxifen ? anastrozole 9 7 2
Tamoxifen ? exemestane 2 1 1
Aromatase
inhibitor ? Tamoxifen
17 13 (76.5) 4 (23.5)
Letrozole ? tamoxifen 8 7 1
Anastrozole ? tamoxifen 6 5 1
Exemestane ? tamoxifen 3 1 2
Aromatase
inhibitor ? Aromatase
inhibitor
29 20 (69.0) 9 (31.0)
Letrozole ? anastrozole 7 4 3
Letrozole ? exemestane 7 5 2
Anastrozole ? letrozole 10 8 2
Anastrozole ? exemestane 5 3 2
a Therapy was continued after drug switch
b Therapy was discontinued or a further switch was made
804 Breast Cancer Res Treat (2011) 129:799–807
123
constellation is clearly not relevant in a situation where the
discontinuation of therapy was not chosen but was man-
datory, for example due to recurrence or the diagnosis of
distant metastases. We think that the synonymous use of the
terms ‘‘discontinuation’’ and ‘‘non-persistence/non-adher-
ence,’’ which was applied by a number of authors [12, 13,
15, 21, 23–30], is a severe methodic error which leads to the
fact that patients who had to stop therapy due to liver
metastases are categorized in the same group with those
who, for example, suffer from hot flashes and those who
stopped the therapy because they have a general mistrust in
the agents of the western medicine.
It was shown that persistence and adherence to endo-
crine therapy was influenced by certain factors such as age,
adverse effects, patient beliefs about the risks and benefits
of drug use, history of medication and good patient-doctor
relationship [2–5, 31]. Some of these factors may be
influenced by the type of care and expertise of the
responsible physician. Since most of the patients in our
study had follow-up at the oncology unit of our department,
the favorable non-persistence rates may be associated with
the fact that all physicians in this unit are not only expe-
rienced in the aftercare of oncologic patients but also
applied the techniques of patient-centered communication
[32, 33]. For many years, in any follow-up consultation of
patients who take adjuvant endocrine treatment, the dialog
with the patient has included targeted questions regarding
therapy motivation, the importance of adherence and in
particular, an open discussion regarding therapy-related
side effects. When patients experience distressing symp-
toms, we carefully evaluate these symptoms and make the
patients feel that their complaints are taken seriously while
offering non-pharmacological and pharmacological mea-
sures to improve the situation. As stated by other authors, a
change in therapy may be an effective strategy to improve
patient persistence and adherence [2, 34]. In our study,
more than 80% of the patients who required a change of the
prescribed agent due to adverse effects could fully com-
plete endocrine therapy in the course of time. In some
cases, patience is required and more than one drug switch
can be necessary. Not only is a switch between different
agent groups (tamoxifen to AI, or AI to tamoxifen) a
possibility, but also a switch within the three different
available aromatase inhibitors (letrozole, anastrozole,
exemestan) might be a promising approach. In our expe-
rience, in cases where a single therapy-related adverse
event led to therapy switch, the likelihood that the therapy
will be continued to the targeted aim is particularly high.
Therefore, patients who suffer from several side effects, in
particular a syndrome-like complex from neuropsychiatric
symptoms (e.g. sleeping difficulties, lightheaded feel-
ing, headaches, mood swings, irritability, lack of energy,
nervous feeling, etc.) run a higher risk of quitting therapy.
In some cases, the side effects are not necessarily severe.
There is increasing recognition of the effect of persistent
low-grade problems which lead to a relevant chronic fati-
gue and could potentially decrease the motivation for
continuation of therapy (citation from an open letter of a
cancer patient to her doctor: ‘‘…the little things that get us
down’’[35]). Correspondingly, patients who suffer from
therapy-related side effects after a planned switch from
tamoxifen to an AI, show a high degree of persistence. In
these cases (in our study cohort: n = 12), a re-switch to
tamoxifen, which was previously given for 2–3 years, is an
easy step to warrant persistence. In our experience, a
switch not only lessens the intensity of adverse side effects
in some cases, but might also support drug persistence:
certain patients who started a certain drug and experienced
side effects, tried another drug, experienced no change or
worse side effects and returned to their initial drug (in our
study cohort, we observed this in 12 cases). We feel that it
is important to accompany these patients during this
month-long conflict between eradication of side effects and
the motivation to treat a potentially life threatening disease
using all possibilities.
We are convinced that great demands are made on the
treating physician (both on a professional and interpersonal
level) when patients question the therapy in conflicting
situations and believe that care in a specialized center can
ensure persistence and adherence to therapy.
However, the limitations of our study must be consid-
ered. First, our study relies on information obtained by
patients‘ self-report of persistence. It is possible that in
some cases the patients who reported continuing their
medication had actually stopped taking it and just gave a
socially acceptable answer. Furthermore, we defined
non-persistence as an intentional action. Atkins et al.
demonstrated a high percentage of 55% of non-adherent
patients with the vast majority of women reporting a non-
intentional non-adherence, i.e. they often just forgot to take
their medication [21]. Waterhouse et al. who examined
adherence to tamoxifen therapy found that self reported
adherence consistently underestimates non-adherence as
determined by more objective measures such as pill count
and microelectronic monitoring [29].
Secondly, one might argue that prospective randomized
clinical trials have the highest level of evidence in medical
literature and might criticize the retrospective approach of
our study. On the other hand, large clinical trials, with their
extensive case documentation requirements cannot provide
exact information regarding persistence and adherence to
endocrine therapy in the general setting, since the readiness
to participate in a trial already creates a certain selection
bias. Furthermore, non-persistence data from clinical trials
may not necessarily be transferable to the real situation,
since withdrawal of study medication does not imply the
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stop of endocrine therapy and a considerable number of the
patients who chose to stop the study medication continued
and completed endocrine therapy outside of the trial [11].
Thirdly, one might argue that the number of the patients
reported in our study is too low to derive meaningful
results. In general, we think that studies on persistence and
adherence to therapy, which in principle try to illuminate
the complex field of personal motivation to therapy, must
be performed in a clinical setting which is able to follow
the entire cohort in a very exact and individual way. We
think that our database fulfills these requirements much
better than epidemiologic studies which might impress
with high numbers, but cannot provide an exact individual-
based follow-up [12, 25].
Conclusions
Our data shows that low non-persistence rates can be
realistically achieved. In cases when therapy-related side
effects occur, a drug switch is a promising step to further
improve persistence and, by doing so, the outcome of
breast cancer patients [31]. We think that this important
issue, which is uncharted territory regarding endocrine
therapy of breast cancer up until now, deserves higher
attention and requires further data analyses.
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